{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:20:31Z","timestamp":1792815631785,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.xphs.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T06:59:30Z","timestamp":1722581970000},"page":"3045-3053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Candesartan Cilexetil Formulations in Mesoporous Silica: Preparation, Enhanced Dissolution In Vitro, and Oral Bioavailability In Vivo"],"prefix":"10.1016","volume":"113","author":[{"given":"Huijian","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-8551","authenticated-orcid":false,"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2024.07.007_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gheart.2015.04.006","article-title":"Reducing cardiovascular mortality through prevention and management of raised blood pressure, a world heart federation roadmap","volume":"10","author":"Adler","year":"2015","journal-title":"Global Heart"},{"issue":"12","key":"10.1016\/j.xphs.2024.07.007_bib0002","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.2020.11289","article-title":"High blood pressure","volume":"324","author":"Desai","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.xphs.2024.07.007_bib0003","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13412","article-title":"Noncoding RNAs in hypertension","volume":"74","author":"Jusic","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.xphs.2024.07.007_bib0004","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol Res"},{"issue":"20","key":"10.1016\/j.xphs.2024.07.007_bib0005","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2174\/0929867329666220829101436","article-title":"Research progress in pharmacological mechanisms, structure-activity relationship and synthesis of sartans","volume":"30","author":"Wang","year":"2022","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.xphs.2024.07.007_bib0006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejps.2017.09.001","article-title":"Development and in vitro\/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil","volume":"109","author":"Aboulfotouh","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.07.007_bib0007","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil, an update of its use in essential hypertension","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.xphs.2024.07.007_bib0008","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11206300-000000000-00000","article-title":"Candesartan cilexetil, in children and adolescents aged 1 to <17 years with hypertension","volume":"10","author":"Hoy","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.xphs.2024.07.007_bib0009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2010.10.013","article-title":"Nanoemulsion improves the oral absorption of candesartan cilexetil in rats, Performance and mechanism","volume":"149","author":"Gao","year":"2011","journal-title":"J Contr Release"},{"issue":"7","key":"10.1016\/j.xphs.2024.07.007_bib0010","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3109\/10717544.2014.945017","article-title":"Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery, in vitro and in vivo evaluation","volume":"23","author":"Surampalli","year":"2014","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xphs.2024.07.007_bib0011","first-page":"264","article-title":"The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS), Beyond guidelines Int","volume":"566","author":"Charalabidis","year":"2019","journal-title":"J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2024.07.007_bib0012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.nano.2011.08.016","article-title":"Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability, in vitro characteristics and absorption mechanism in rats","volume":"8","author":"Zhang","year":"2012","journal-title":"Nanomed Nanotechnol Bio Med"},{"issue":"1","key":"10.1016\/j.xphs.2024.07.007_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/s12249-009-9347-6","article-title":"Solid self-microemulsifying formulation for candesartan cilexetil","volume":"11","author":"Nekkanti","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"10.1016\/j.xphs.2024.07.007_bib0014","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1016\/j.xphs.2019.07.004","article-title":"A self-nanoemulsifying drug delivery system for enhancing the oral bioavailability of candesartan cilexetil, Ex vivo and in vivo evaluation","volume":"108","author":"Aboulfotouh","year":"2019","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.07.007_bib0015","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1208\/s12249-017-0717-1","article-title":"Stabilization and amorphization of lovastatin using different types of silica","volume":"18","author":"Khanfar","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2024.07.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2020.110541","article-title":"Ibuprofen incorporated into unmodified and modified mesoporous silica, from matrix synthesis to drug release","volume":"310","author":"Inoc\u00eancio","year":"2021","journal-title":"Micropor Mesopor Mater"},{"key":"10.1016\/j.xphs.2024.07.007_bib0017","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.msec.2016.12.122","article-title":"Basic evaluation of typical nanoporous silica nanoparticles in being drug carrier, Structure, wettability and hemolysis","volume":"73","author":"Li","year":"2017","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.xphs.2024.07.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105184","article-title":"Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery","volume":"143","author":"Mehmood","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.07.007_bib0019","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.apsusc.2016.10.183","article-title":"Impact of physicochemical properties of porous silica materials conjugated with dexamethasone via pH-responsive hydrazone bond on drug loading and release behavior","volume":"396","author":"Numpilai","year":"2017","journal-title":"Appl Surf Sci"},{"key":"10.1016\/j.xphs.2024.07.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2020.110389","article-title":"Mesoporous silica nanospheres as nanocarriers for poorly soluble drug itraconazole with high loading capacity and enhanced bioavailability","volume":"305","author":"Ren","year":"2020","journal-title":"Micropor Mesopor Mater"},{"issue":"1-2","key":"10.1016\/j.xphs.2024.07.007_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2011.05.021","article-title":"Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole","volume":"414","author":"Kinnari","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.07.007_bib0022","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.colsurfa.2017.02.007","article-title":"Microwave processed solid dispersions for enhanced dissolution of gemfibrozil using non-ordered mesoporous silica","volume":"520","author":"Hussain","year":"2017","journal-title":"Colloid Surface A"},{"key":"10.1016\/j.xphs.2024.07.007_bib0023","article-title":"Cephalexin loading and controlled release studies on mesoporous silica functionalized with amino groups","volume":"72","author":"Montiel-Centeno","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2024.07.007_bib0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpha.2018.01.004","article-title":"Enhancing the dissolution of phenylbutazone using Syloid\u00ae based mesoporous silicas for oral equine applications","volume":"8","author":"Waters","year":"2018","journal-title":"J Pharm Anal"},{"issue":"1","key":"10.1016\/j.xphs.2024.07.007_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/10717544.2014.913323","article-title":"High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica, a comparison of spray drying versus solvent impregnation methods","volume":"23","author":"Hong","year":"2016","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2024.07.007_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.22159\/ijap.2019v11i2.30411","article-title":"Enhancement of dissolution and stability of candesartan cilexetil\u2013loaded silica polymers","volume":"11","author":"Khanfar","year":"2019","journal-title":"Int J Appl Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.07.007_bib0027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/10717544.2013.838715","article-title":"Synthesis and surface modification of mesoporous silica nanoparticles and its application as carriers for sustained drug delivery","volume":"21","author":"Ahmadi","year":"2014","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xphs.2024.07.007_bib0028","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.matchemphys.2017.01.061","article-title":"A convenient solvothermal method to synthesize highly ordered mesoporous silica SBA-15 with high loading of amino groups","volume":"192","author":"Ding","year":"2017","journal-title":"Mater Chem Phys"},{"key":"10.1016\/j.xphs.2024.07.007_bib0029","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cca.2013.04.014","article-title":"Simultaneous UPLC\u2013MS\/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma","volume":"423","author":"Juenke","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"11","key":"10.1016\/j.xphs.2024.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/pharmaceutics12111047","article-title":"Enhancing the oral bioavailability of candesartan cilexetil loaded nanostructured lipid carriers, in vitro characterization and absorption in rats after oral administration","volume":"12","author":"Anwar","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.07.007_bib0031","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jddst.2018.12.016","article-title":"Modified mesoporous silica nanoparticles coated by polymer complex as novel curcumin delivery carriers","volume":"49","author":"Szegedi","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2024.07.007_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.msec.2015.09.095","article-title":"Impact of pore characteristics of silica materials on loading capacity and release behavior of ibuprofen","volume":"59","author":"Numpilai","year":"2016","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.xphs.2024.07.007_bib0033","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jnoncrysol.2016.01.020","article-title":"Release of flurbiprofen using of SBA-15 mesoporous silica, Influence of silica sources and functionalization","volume":"437","author":"Yilmaz","year":"2016","journal-title":"J Non-Cryst Solids"},{"key":"10.1016\/j.xphs.2024.07.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2022.111862","article-title":"Effect of surface functionalization and pore structure type on the release performance of mesoporous silica nanoparticles","volume":"336","author":"Peng","year":"2022","journal-title":"Micropor Mesopor Mater"},{"key":"10.1016\/j.xphs.2024.07.007_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.micromeso.2017.11.009","article-title":"Modelling the adsorption and controlled release of drugs from the pure and amino surface-functionalized mesoporous silica hosts","volume":"262","author":"Mart\u00edn","year":"2018","journal-title":"Micropor Mesopor Mater"},{"key":"10.1016\/j.xphs.2024.07.007_bib0036","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2016.12.043","article-title":"In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation","volume":"250","author":"McCarthy","year":"2017","journal-title":"J Contr Release"},{"issue":"5","key":"10.1016\/j.xphs.2024.07.007_bib0037","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1208\/s12249-020-01685-1","article-title":"In vitro-in vivo correlation for solid dispersion of a poorly water-soluble drug efonidipine hydrochloride","volume":"21","author":"Cheng","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"10.1016\/j.xphs.2024.07.007_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1208\/s12249-021-02117-4","article-title":"Altered media flow and tablet position as factors of how air bubbles affect dissolution of disintegrating and non-disintegrating tablets using a USP 4 flow-through cell apparatus","volume":"22","author":"Yoshida","year":"2021","journal-title":"AAPS Pharm Sci Tech"},{"key":"10.1016\/j.xphs.2024.07.007_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119130","article-title":"Flow-through cell-based in vitro release method for triamcinolone acetonide poly (lactic-co-glycolic) acid microspheres","volume":"579","author":"Tipnis","year":"2020","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2024.07.007_bib0040","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1021\/acs.molpharmaceut.0c00488","article-title":"Influence of drug\u2013silica electrostatic interactions on drug release from mesoporous silica-based oral delivery systems","volume":"17","author":"Hate","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.07.007_bib0041","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msec.2013.08.014","article-title":"Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug, Influence of pore size on release rate","volume":"34","author":"Zhu","year":"2014","journal-title":"Mat Sci Eng C"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T16:48:39Z","timestamp":1727887719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0022354924002533"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.07.007","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candesartan Cilexetil Formulations in Mesoporous Silica: Preparation, Enhanced Dissolution In Vitro, and Oral Bioavailability In Vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}